신경질환용 유전자 치료 시장 보고서(2026년)

Gene therapy for neurological diseases involves using genetic material to treat or prevent disorders that affect the brain, spinal cord, and nervous system. This approach delivers corrective genes into a patient's cells using viral or non-viral vectors to address the underlying genetic causes of neurological conditions. It aims to restore normal gene function, slow disease progression, or alleviate symptoms by targeting the root genetic causes rather than merely managing symptoms.

The main types of gene therapy for neurological diseases are viral gene therapy and non-viral gene therapy. Viral gene therapy uses engineered viruses as delivery vectors to transport therapeutic genes into a patient's cells for the treatment or prevention of disease. These therapies target a range of neurological conditions, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, and multiple sclerosis. They can be administered via various routes, such as intravenous, intrathecal, intranasal, and intracerebral methods, and are applied in different settings, including hospitals, clinics, and other healthcare facilities.

Tariffs have impacted the gene therapy for neurological diseases market by increasing the cost of imported viral vectors, nanoparticles, and specialized delivery equipment, leading to higher treatment costs and supply chain disruptions. Segments like viral gene therapies and advanced non-viral delivery systems are most affected, particularly in North America and Europe. On the positive side, tariffs have encouraged domestic production of vectors and delivery technologies, promoted local innovation, and accelerated development of cost-effective gene therapy solutions.

The gene therapy on neurological diseases market research report is one of a series of new reports from The Business Research Company that provides gene therapy on neurological diseases market statistics, including gene therapy on neurological diseases industry global market size, regional shares, competitors with a gene therapy on neurological diseases market share, detailed gene therapy on neurological diseases market segments, market trends and opportunities, and any further data you may need to thrive in the gene therapy on neurological diseases industry. This gene therapy on neurological diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gene therapy on neurological diseases market size has grown rapidly in recent years. It will grow from $3.55 billion in 2025 to $4.01 billion in 2026 at a compound annual growth rate (CAGR) of 13.0%. The growth in the historic period can be attributed to limited gene therapy options for neurological diseases, growing prevalence of alzheimer's and parkinsons disease, reliance on conventional treatment methods, increasing awareness of genetic approaches, early clinical trials of viral vectors.

The gene therapy on neurological diseases market size is expected to see rapid growth in the next few years. It will grow to $6.48 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to development of adeno associated virus and lentiviral therapies, expansion of non-viral delivery platforms, increasing regulatory approvals for neurological gene therapies, rising investment in r&d for targeted genetic interventions, integration of digital monitoring and AI-based patient management. Major trends in the forecast period include rising investment in viral and non-viral gene therapy platforms, expansion of gene therapy applications across neurological disorders, increasing focus on personalized and targeted genetic treatments, growth in hospital and clinic-based gene therapy programs, development of advanced delivery methods for neurological gene therapy.

The rising prevalence of neurological disorders is expected to drive the growth of the gene therapy for neurological diseases market in the coming years. Neurological disorders are medical conditions that affect the brain, spinal cord, and nerves, causing a variety of cognitive, motor, and sensory impairments. The increasing prevalence of these disorders is closely linked to aging, which gradually impairs neuronal function, reduces brain plasticity, and increases oxidative stress, contributing to disease onset and progression. Gene therapy for neurological diseases supports the management of these conditions by addressing underlying genetic causes, offering the potential for long-term or permanent treatment solutions. It improves patient outcomes by restoring or modifying gene function, alleviating symptoms, and minimizing the need for repeated interventions, thereby enhancing overall quality of life. For example, according to the National Health Service in the UK, by June 30, 2024, there were 487,432 patients diagnosed with dementia-a progressive brain disorder affecting memory, thinking, and daily activities-representing an increase of 3,155 cases compared to May 31, 2024. This growing prevalence of neurological disorders is thus supporting the expansion of the gene therapy for neurological diseases market.

Leading companies in this market are focusing on advanced viral delivery systems, such as adeno-associated virus serotype 2 (AAV2) vectors, to improve targeted gene delivery, enhance efficacy, reduce immune responses, and enable long-lasting treatments. AAV2 vectors are modified, non-pathogenic viral systems used in gene therapy to transport therapeutic genes into target cells, particularly neurons, for sustained expression. For instance, in November 2024, PTC Therapeutics Inc., a US-based biopharmaceutical company, received FDA approval for a gene therapy to treat aromatic L-amino acid decarboxylase (AADC) deficiency. This therapy uses an AAV2 vector to deliver a functional copy of the DDC gene into the putamen, restoring dopamine production and improving motor function. The therapy is administered as a one-time intraputaminal infusion, providing long-term therapeutic benefits and significantly reducing debilitating symptoms without repeated interventions.

In January 2023, Neurocrine Biosciences Inc., a US-based biotechnology company, partnered with Voyager Therapeutics Inc. to advance next-generation gene therapies for neurological diseases. Through this collaboration, Neurocrine and Voyager aim to accelerate development and commercialization by combining Voyager's TRACER capsid platform-enabled GBA1 gene therapy and other CNS-targeted AAV programs with Neurocrine's neuroscience and clinical expertise. The partnership allows for risk-sharing, cost and profit alignment, and the pursuit of novel treatments for Parkinson's disease, Friedreich's ataxia, and other rare CNS disorders. Voyager Therapeutics Inc., based in the US, specializes in developing AAV-based gene therapies with enhanced blood-brain barrier penetration for central nervous system conditions.

Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG

North America was the largest region in the gene therapy on neurological diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gene therapy on neurological diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gene therapy on neurological diseases market consists of revenues earned by entities by providing services such as gene delivery and vector development, clinical trial services, personalised therapy development, regulatory consulting and compliance, and manufacturing support. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene therapy on neurological diseases market also includes sales of gene therapy vectors, plasmid deoxyribonucleic acid (DNA), ribonucleic acid (RNA)-based therapeutics, cell lines and reagents, and neurologically targeted gene therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gene Therapy On Neurological Diseases Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses gene therapy on neurological diseases market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gene therapy on neurological diseases ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gene therapy on neurological diseases market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Viral Gene Therapy; Non-Viral Gene Therapy
• 2) By Target Disease: Alzheimer's Disease; Parkinsons Disease; Amyotrophic Lateral Sclerosis (ALS); Huntington's Disease; Multiple Sclerosis
• 3) By Administration Route: Intravenous; Intrathecal; Intranasal; Intracerebral; Other Administration Routes
• 4) By Application: Hospital; Clinic; Other Applications
• Subsegments:
• 1) By Viral Gene Therapy Type: Adeno Associated Virus; Lentivirus; Retrovirus; Herpes Simplex Virus; Adenovirus
• 2) By Non-Viral Gene Therapy Type: Liposomes; Nanoparticles; Electroporation; Gene Gun; Naked Plasmid Deoxyribonucleic Acid (DNA)
• Companies Mentioned: Novartis AG; Biogen Inc.; Sarepta Therapeutics Inc.; PTC Therapeutics Inc.; Oxford Biomedica plc; Regenxbio Inc.; Passage Bio Inc.; Intellia Therapeutics Inc.; Voyager Therapeutics Inc.; UniQure N.V.; AviadoBio Ltd.; Capsida Biotherapeutics Inc.; StrideBio Inc.; Lysogene S.A.; Wave Life Sciences Ltd.; Taysha Gene Therapies Inc.; Abeona Therapeutics Inc.; CRISPR Therapeutics AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Gene Therapy On Neurological Diseases Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Gene Therapy On Neurological Diseases Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Gene Therapy On Neurological Diseases Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Gene Therapy On Neurological Diseases Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Investment In Viral And Non-Viral Gene Therapy Platforms
  • 4.2.2 Expansion Of Gene Therapy Applications Across Neurological Disorders
  • 4.2.3 Increasing Focus On Personalized And Targeted Genetic Treatments
  • 4.2.4 Growth In Hospital And Clinic-Based Gene Therapy Programs
  • 4.2.5 Development Of Advanced Delivery Methods For Neurological Gene Therapy

5. Gene Therapy On Neurological Diseases Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Neurology Research Centers
• 5.4 Specialty Treatment Centers
• 5.5 Academic And Research Institutions

6. Gene Therapy On Neurological Diseases Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Gene Therapy On Neurological Diseases Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Gene Therapy On Neurological Diseases PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Gene Therapy On Neurological Diseases Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Gene Therapy On Neurological Diseases Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Gene Therapy On Neurological Diseases Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Gene Therapy On Neurological Diseases Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Gene Therapy On Neurological Diseases Market Segmentation

• 9.1. Global Gene Therapy On Neurological Diseases Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Viral Gene Therapy, Non-Viral Gene Therapy
• 9.2. Global Gene Therapy On Neurological Diseases Market, Segmentation By Target Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Alzheimer's Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease, Multiple Sclerosis
• 9.3. Global Gene Therapy On Neurological Diseases Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes
• 9.4. Global Gene Therapy On Neurological Diseases Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital, Clinic, Other Applications
• 9.5. Global Gene Therapy On Neurological Diseases Market, Sub-Segmentation Of Viral Gene Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus
• 9.6. Global Gene Therapy On Neurological Diseases Market, Sub-Segmentation Of Non-Viral Gene Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)

10. Gene Therapy On Neurological Diseases Market Regional And Country Analysis

• 10.1. Global Gene Therapy On Neurological Diseases Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Gene Therapy On Neurological Diseases Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Gene Therapy On Neurological Diseases Market

• 11.1. Asia-Pacific Gene Therapy On Neurological Diseases Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Gene Therapy On Neurological Diseases Market

• 12.1. China Gene Therapy On Neurological Diseases Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Gene Therapy On Neurological Diseases Market

• 13.1. India Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Gene Therapy On Neurological Diseases Market

• 14.1. Japan Gene Therapy On Neurological Diseases Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Gene Therapy On Neurological Diseases Market

• 15.1. Australia Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Gene Therapy On Neurological Diseases Market

• 16.1. Indonesia Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Gene Therapy On Neurological Diseases Market

• 17.1. South Korea Gene Therapy On Neurological Diseases Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Gene Therapy On Neurological Diseases Market

• 18.1. Taiwan Gene Therapy On Neurological Diseases Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Gene Therapy On Neurological Diseases Market

• 19.1. South East Asia Gene Therapy On Neurological Diseases Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Gene Therapy On Neurological Diseases Market

• 20.1. Western Europe Gene Therapy On Neurological Diseases Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Gene Therapy On Neurological Diseases Market

• 21.1. UK Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Gene Therapy On Neurological Diseases Market

• 22.1. Germany Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Gene Therapy On Neurological Diseases Market

• 23.1. France Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Gene Therapy On Neurological Diseases Market

• 24.1. Italy Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Gene Therapy On Neurological Diseases Market

• 25.1. Spain Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Gene Therapy On Neurological Diseases Market

• 26.1. Eastern Europe Gene Therapy On Neurological Diseases Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Gene Therapy On Neurological Diseases Market

• 27.1. Russia Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Gene Therapy On Neurological Diseases Market

• 28.1. North America Gene Therapy On Neurological Diseases Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Gene Therapy On Neurological Diseases Market

• 29.1. USA Gene Therapy On Neurological Diseases Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Gene Therapy On Neurological Diseases Market

• 30.1. Canada Gene Therapy On Neurological Diseases Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Gene Therapy On Neurological Diseases Market

• 31.1. South America Gene Therapy On Neurological Diseases Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Gene Therapy On Neurological Diseases Market

• 32.1. Brazil Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Gene Therapy On Neurological Diseases Market

• 33.1. Middle East Gene Therapy On Neurological Diseases Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Gene Therapy On Neurological Diseases Market

• 34.1. Africa Gene Therapy On Neurological Diseases Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Gene Therapy On Neurological Diseases Market, Segmentation By Type, Segmentation By Target Disease, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Gene Therapy On Neurological Diseases Market Regulatory and Investment Landscape

36. Gene Therapy On Neurological Diseases Market Competitive Landscape And Company Profiles

• 36.1. Gene Therapy On Neurological Diseases Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Gene Therapy On Neurological Diseases Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Gene Therapy On Neurological Diseases Market Company Profiles
  • 36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. PTC Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Oxford Biomedica plc Overview, Products and Services, Strategy and Financial Analysis

37. Gene Therapy On Neurological Diseases Market Other Major And Innovative Companies

• Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG

38. Global Gene Therapy On Neurological Diseases Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Gene Therapy On Neurological Diseases Market

40. Gene Therapy On Neurological Diseases Market High Potential Countries, Segments and Strategies

• 40.1 Gene Therapy On Neurological Diseases Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Gene Therapy On Neurological Diseases Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Gene Therapy On Neurological Diseases Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer